A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability

Objectives: In this study, patients with painful diabetic neuropathy were trained using an experimental pain paradigm in an attempt to enroll a subset of patients who are pain connoisseurs and therefore more able to discriminate between active and placebo treatments. Methods: AZD5213, a novel histamine H3 receptor inverse agonist+pregabalin, pregabalin, and placebo were then tested in a 3-period cross-over. Results: The study did not provide any evidence of clinical efficacy for AZD5213 when combined with pregabalin in the treatment of painful diabetic neuropathy. Discussion: The training of study patients in pain reporting and subsequent enrichment with good pain reporters also did not enable the robust detection of the efficacy of pregabalin relative to placebo in a small sample size. Further work is required before recommending the use of connoisseur patients in future neuropathic pain studies.

Automated summary

The study found no evidence of clinical efficacy for AZD5213 combined with pregabalin in treating painful diabetic neuropathy. Training patients in pain reporting and enriching with good pain reporters did not enable robust detection of pregabalin's efficacy relative to placebo in a small sample size, suggesting further work is needed before recommending the use of connoisseur patients in future neuropathic pain studies.